Accordingly, the present disclosure concerns compounds and compositions that can deliver 3APS by minimizing the metabolism, e.g., first-pass metabolism, associated with that drug, and more particularly compounds that would block or protect the amino group of 3APS such that it avoids metabolism, e.g., by transaminases and/or monoamine oxidases.

The present disclosure includes methods, compounds, compositions and vehicles for delivering in a subject, preferably a human subject, 3-amino-1-propanesulfonic acid, or salts thereof. 3-Amino-1-propanesulfonic acid (also named 3APS, Tramiprosate, Alzhemed™) has the structure:



3APS

The present disclosure relates to compounds or compositions that will yield or generate 3APS after administered in a subject. In one embodiment, the compound that will yield or generate 3APS is an amino acid prodrug of 3APS. In another embodiment, the compound that will yield or generate 3APS is a carbamate prodrug of 3APS. In another embodiment, the compound that will yield or generate 3APS is an amide prodrug of 3APS. In another embodiment, the compound that will yield or generate 3APS is a carbohydrate-derived prodrug of 3APS. In another

25. A pharmaceutical composition for use in treating or preventing a neurodegenerative disease, comprising a prodrug of claim 14 together with a pharmaceutically acceptable carrier.

26. Use of the prodrug of claim 14 in the manufacture of a medicament for treating or preventing a neurodegenerative disease.

27. A process for converting a compound of any one of claims 1 to 4, to 3-amino-1-propanesulfonic acid, comprising contacting said compound with an enzyme which metabolizes said compound to 3-amino-1-propanesulfonic acid *in vitro*.

28. The process of claim 27, comprising contacting said compound with plasma, blood, brain cells or any combination thereof.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

ABSTRACT

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either *in vitro* or *in vivo*. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

[No available figure]